These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20017158)

  • 1. Hepatic ablation for neuroendocrine tumor metastases.
    Maithel SK; Fong Y
    J Surg Oncol; 2009 Dec; 100(8):635-8. PubMed ID: 20017158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases.
    Berber E; Flesher N; Siperstein AE
    World J Surg; 2002 Aug; 26(8):985-90. PubMed ID: 12016479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic neuroendocrine hepatic tumors: resection improves survival.
    Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
    Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
    Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
    Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience.
    Gillams A; Cassoni A; Conway G; Lees W
    Abdom Imaging; 2005; 30(4):435-41. PubMed ID: 15759207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin release during percutaneous radiofrequency ablation in a patient with symptomatic liver metastases of a neuroendocrine tumor.
    Wettstein M; Vogt C; Cohnen M; Brill N; Kurz AK; Mödder U; Häussinger D
    Hepatogastroenterology; 2004; 51(57):830-2. PubMed ID: 15143927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach.
    Saxena A; Chua TC; Sarkar A; Chu F; Liauw W; Zhao J; Morris DL
    Surgery; 2011 Feb; 149(2):209-20. PubMed ID: 20674950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.
    Ueno S; Sakoda M; Kubo F; Hiwatashi K; Tateno T; Baba Y; Hasegawa S; Tsubouchi H;
    J Hepatobiliary Pancreat Surg; 2009; 16(3):359-66. PubMed ID: 19300896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
    Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
    Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiofrequency ablation of neuroendocrine liver metastases.
    Elvin A; Skogseid B; Hellman P
    Abdom Imaging; 2005; 30(4):427-34. PubMed ID: 15791486
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques.
    Atwell TD; Charboneau JW; Que FG; Rubin J; Lewis BD; Nagorney DM; Callstrom MR; Farrell MA; Pitot HC; Hobday TJ
    Cardiovasc Intervent Radiol; 2005; 28(4):409-21. PubMed ID: 16041556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiofrequency ablation of neuroendocrine hepatic metastasis.
    Gamblin TC; Christians K; Pappas SG
    Surg Oncol Clin N Am; 2011 Apr; 20(2):273-9, vii-viii. PubMed ID: 21377583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases.
    Oshowo A; Gillams A; Harrison E; Lees WR; Taylor I
    Br J Surg; 2003 Oct; 90(10):1240-3. PubMed ID: 14515293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
    Chambers AJ; Pasieka JL; Dixon E; Rorstad O
    Surgery; 2008 Oct; 144(4):645-51; discussion 651-3. PubMed ID: 18847650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical therapy of liver metastases.
    Kuvshinoff B; Fong Y
    Semin Oncol; 2007 Jun; 34(3):177-85. PubMed ID: 17560979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
    Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
    Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours.
    Norlén O; Stålberg P; Zedenius J; Hellman P
    Br J Surg; 2013 Oct; 100(11):1505-14. PubMed ID: 24037573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal cytoreduction after combined resection and radiofrequency ablation of hepatic metastases from recurrent malignant ovarian tumors.
    Mateo R; Singh G; Jabbour N; Palmer S; Genyk Y; Roman L
    Gynecol Oncol; 2005 Apr; 97(1):266-70. PubMed ID: 15790474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rational approach to the use of hepatic transplantation in the treatment of metastatic neuroendocrine tumors.
    Curtiss SI; Mor E; Schwartz ME; Sung MW; Hytiroglou P; Thung SN; Sheiner PA; Emre S; Miller CM
    J Am Coll Surg; 1995 Feb; 180(2):184-7. PubMed ID: 7850052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.
    Sarmiento JM; Heywood G; Rubin J; Ilstrup DM; Nagorney DM; Que FG
    J Am Coll Surg; 2003 Jul; 197(1):29-37. PubMed ID: 12831921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.